Pharmacy Times

OCTOBER 14, 2022

A presentation at the AMCP Nexus conference focuses on the health care disparities and pharmacotherapy options for gender affirmation.

181

181

Drug Topics

OCTOBER 14, 2022

A new study shows the AD drug does not interfere with vaccinations or increase severity.

Vaccines 187

Vaccines 187

Pharmacy Times

OCTOBER 14, 2022

Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.

161

161

STAT

OCTOBER 14, 2022

On Sunday, the New England Journal of Medicine published the interim results of a landmark trial examining the effect of inviting people to colonoscopy screening. The paper, which STAT covered , exploded across medical media and ignited debate over the trial’s results, how to interpret those results, and the popular coverage of the study. The frenzy resulted over the trial’s main finding — which is that offering colonoscopies to people did not reduce cancer deaths within a 1

128

128

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

OCTOBER 14, 2022

At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.

144

144

pharmaphorum

OCTOBER 14, 2022

A consortium of industry and academic groups – led by Johnson & Johnson’s pharma division Janssen – has been set up to tackle the environmental impact of digital health products, specifically aimed at minimising waste that could end up in landfill. The Digital Health in a Circular Economy (DiCE) group was formed earlier this year with the aim of developing ways to “design, collect, directly reuse, refurbish, remanufacture, and recycle digital health devices.” The programme

Labelling 124

Labelling 124

STAT

OCTOBER 14, 2022

In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities.   Scrambling for a solution, the company’s leadership traded ideas for new ways of ensuring its pharmacies would stop filling medically illegitimate prescriptions.

Documentation 118

Documentation 118

Pharmacy Times

OCTOBER 14, 2022

As a part of the Women in Pharmacy series, Vibhuti Arya, PharmD, MPH, FAPhA, global lead, Gender Equity and Diversity Workforce Development at FIP, discusses moments that shaped her vision for her career in pharmacy.

123

123

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs. They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccines 115

Vaccines Research Laboratories Immunization 115

Pharmacy Times

OCTOBER 14, 2022

Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.

123

123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

European Pharmaceutical Review

OCTOBER 14, 2022

RemeGen has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG). Telitacicept is a proprietary novel fusion protein from RemeGen to treat autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallisable

FDA 111

FDA Immunization 111

Pharmacy Times

OCTOBER 14, 2022

Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.

123

123

Drug Topics

OCTOBER 14, 2022

Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.

112

112

Pharmacy Times

OCTOBER 14, 2022

The process of supporting a cause for our profession can be highly rewarding. As pharmacists, we must take charge to enact change.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

OCTOBER 14, 2022

Insurance giant UnitedHealth Group’s strong financial showing in the third quarter was driven in part by its fast-growing provider segment, Optum Health.  UnitedHealth’s network of outpatient clinics and roughly 60,000 doctors is already more profitable than the company’s larger insurance division, UnitedHealthcare. UnitedHealth’s CEO outlined the company’s plans to expand Optum Health’s reach even further on an investor call Friday.

Insurance 104

Insurance 104

pharmaphorum

OCTOBER 14, 2022

Biotech company Odyssey Therapeutics, Inc. has announced a $168 million Series B financing, led by global venture capital firm General Catalyst, an active investor in the healthcare sector. The proceeds are to advance Odyssey’s precision immunomodulator and oncology medicine portfolio. The latest funding announcement follows the company’s $218 million Series A financing in December 2021 and brings the total capital raised to $386 million – enabling continuance of Odyssey’s mission to devel

103

103

STAT

OCTOBER 14, 2022

With health emergencies becoming more common, the world needs more efficient ways to test the safety and effectiveness of drugs, even if they haven’t yet completed the lengthy series of clinical trials the Food and Drug Administration usually requires. Data from the real-world use of new drugs offers an increasingly valuable and efficient way to do this.

Vaccines 100

Vaccines 100

The Thyroid Pharmacist

OCTOBER 14, 2022

I first learned about S. boulardii as a young pharmacist. It is a beneficial yeast (also known as a probiotic yeast) that is often recommended to people who take antibiotics, to counteract the gut imbalance that can occur when antibiotics kill off our “good” bacteria, in addition to any of the pathogenic bacteria they were initially taken to kill. This particular probiotic is thought to be most effective in restoring dysbiosis from antibiotics because, in contrast to most probiotics which are ba

Health and Personal Care Stores 99

Health and Personal Care Stores Immunization Dosage 99

STAT

OCTOBER 14, 2022

Amid rising concern over antibiotic resistance, a new report finds that a dozen of the leading grocery chains in the U.S. are largely failing to take steps that are needed to prevent the spread of so-called superbugs in the food supply chain. In general, most of the companies lack any meaningful policies requiring their meat and poultry suppliers to eliminate the overuse of antibiotics.

98

98

pharmaphorum

OCTOBER 14, 2022

Day 3 coverage: Click here to read Reuters: Pharma 2022 Day 1 overview. Click here or the image below to read Reuters: Pharma 2022 Day 2 coverage. The post Reuters Pharma 2022 – Day 3 coverage appeared first on.

98

98

STAT

OCTOBER 14, 2022

When Hurricane Fiona knocked out power across the entire island of Puerto Rico, hospitals turned to diesel-fueled generators to keep the lights on and critical machines running. Community health centers — often the most accessible medical facilities in the poorest districts of the island, those hardest hit by hurricanes — couldn’t immediately do the same.

Hospitals 98

Hospitals 98

Digital Pharmacist

OCTOBER 14, 2022

Pharmacy Week is almost here and what an exciting time is it! Pharmacy Week takes place during the 3 rd week of October each year. According to ASHP, this week is “a time to recognize the powerful impact you make on your patients”. No better time to celebrate your pharmacy teams and their impact as well as your incredible patients than Pharmacy Week. .

98

98

STAT

OCTOBER 14, 2022

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

98

98

Pharmacy Times

OCTOBER 14, 2022

Research indicates quadruplet regimens may be a viable option for this disease.

132

132

pharmaphorum

OCTOBER 14, 2022

In this article, Research Partnership reviews why the path to commercialisation for the half a dozen approvals in Europe over the last few years has not been smooth, and shares feedback gathered from our payer network on the outlook for gene therapy market access in Europe, especially considering the shift to more prevalent diseases. In January, the Alliance for Regenerative Medicine (ARM)’s Cell and Gene State of the Industry briefing earmarked 2022 as a record year for approval of gene therapi

Communication 81

Communication 81

Pharmacy Times

OCTOBER 14, 2022

Presentation at the AMCP Nexus conference focuses on midterm election outlook and a plug for the Pre-approval Information Exchange Act.

122

122

European Pharmaceutical Review

OCTOBER 14, 2022

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. The data demonstrated that uptake in the US continues to grow and has created a large market share in most therapeutic areas where biosimilars have been launched.

FDA 78

FDA 78

Drug Topics

OCTOBER 14, 2022

Your weekly roundup of the latest news from Drug Topics®.

98

98

Pharmacy Times

OCTOBER 14, 2022

The drug shows improvement in exercise capacity and key secondary outcomes compared with the placebo when added to background therapy for those with pulmonary arterial hypertension.

65

65

Pharmaceutical Commerce

OCTOBER 14, 2022

How to navigate the ongoing temperature challenges surrounding storage & distribution.

98

98

Pharmacy Times

OCTOBER 14, 2022

As part of American Pharmacist Month, Pharmacy Times is asking experts what they believe the value of the pharmacist is.

81

81

Drug Topics

OCTOBER 14, 2022

Share your thoughts on this year in review.

98

98

Pharmacy Times

OCTOBER 14, 2022

The study will evaluate the safety, tolerability, and efficacy of the in combination in patients both with and without prior exposure to a KRASG12C inhibitor.

65

65

pharmaphorum

OCTOBER 14, 2022

Bayer’s big-selling contraceptive Mirena has been approved in Europe to provide up to eight years of pregnancy protection, which the company says is the longest of any device of its kind. The approval under the European Workshare Procedure also covers use of Mirena for the treatment of idiopathic menorrhagia (heavy menstrual bleeding) for up to eight years, according to the pharma group.

Labelling 59

Labelling FDA 59